Section 5: Patient Safety and Quality Assurance

5PSQ-120

IMPACT OF THE COVID-19 PANDEMIC ON THE USE OF ANTIMICROBIALS IN PRIMARY AND HOSPITAL CARE

5PSQ-118

LITHIUM THERAPY ON HOSPITAL ADMISSION

5PSQ-117

DETERMINATION OF GENETIC POLYMORPHISMS IN THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN A PATIENT WITH GASTRIC ADENOCARCINOMA TREATED WITH FLUOROPYRIMIDINES: A CASE REPORT

5PSQ-115​

ANALYSIS OF MEDICATION ERRORS INVOLVING HIGH-RISK PATIENTS IN THE PERIOPERATIVE SETTING

5PSQ-112

HIDDEN HARM? ASSESSING MAGNITUDE AND COSTS OF INTRAVENOUS THERAPY ADMINISTRATION ERRORS VIA SMART PUMP REPORTS

5PSQ-105

INSULIN PERFUSION IN NEONATOLOGY. WHICH ONE IS THE SAFEST?

5PSQ-095

COMPARISON BETWEEN THE MAXIMUM RECOMMENDED DOSE OF AZATHIOPRINE ACCORDING TO THE ENZYMATIC ACTIVITY OF THIOPURINE METHYLTRANSFERASE AND 6-THIOGUANINE LEVELS WITH THE MAXIMUM TOLERATED DOSE

5PSQ-093

PERSISTENCE OF TREATMENT WITH INTERLEUKIN -17 INHIBITORS IN SKIN DISORDERS

5PSQ-087

LONG-TERM DUAL ANTIPLATELET THERAPY: CONTROVERSY CONTINUES

5PSQ-085

REAL-WORLD SAFETY AND TOLERABILITY OF PALBOCICLIB AS FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER

5PSQ-083

USE OF ISAVUCONAZOLE IN PATIENTS WITH COVID19 IN AN INTENSIVE CARE UNIT

5PSQ-081

IMPACT OF PHARMACY INTERVENTION ON REDUCTION OF MEDICATION-RELATED PROBLEMS IN ELDERLY PATIENTS IN A NURSING HOME

5PSQ-078

THROMBOEMBOLIC PROPHYLAXIS IN PATIENTS TREATED WITH ORAL IMMUNOMODULATORS IN MULTIPLE MYELOMA

5PSQ-071​

REAL-WORLD RESULTS OF EFFECTIVENESS AND SECURITY OF ERENUMAB AND GALCANEZUMAB IN MIGRAINE PATIENTS

5PSQ-070

USEFULNESS OF PHARMACEUTICAL VALIDATION IN CHEMOTHERAPY PRESCRIPTION

Pages